New mRNA delivery platform uses engineered extracellular vesicles
Engineered extracellular vesicles that deliver full-length DMD mRNA to skeletal muscle restored dystrophin production and significantly improved muscle strength and function in Duchenne muscular dystrophy models without notable toxicity. The post New mRNA Delivery Platform Restores Muscle Function in DMD Models appeared first on GEN - Genetic Engineering and Biotechnology News. The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
- Published by
- GEN — Genetic Engineering & Biotechnology News
- Evidence type
- Industry
GEN reports: Engineered extracellular vesicles that deliver full-length DMD mRNA to skeletal muscle restored dystrophin production and significantly improved muscle strength and function in Duchenne muscular dystrophy models without notable toxicity. The post New mRNA Delivery Platform Restores Muscle Function in DMD Models appeared first on GEN - Genetic Engineering and Biotechnology News.
The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit. Consult the linked GEN report for the source organisation’s full announcement.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.
Prefer to talk it through? Book a 30-minute discovery call